| 作者：Michael O'Riordan | | 出處：WebMD醫學新聞 |
August 28, 2008 — 根據一篇新研究，在最近兩年，有關腫瘤、內分泌與呼吸道疾病的研究數量越來越多，而心臟病方面的研究則呈減少；根據該報告，癌症是最常被研究的疾病，而心臟科方面的研究數量排於中樞神經系統異常研究之後，名列第三。
香港大學的Johan Karlberg醫師在8月25日Nature期刊中發表的臨床試驗回顧中寫道，乳癌和肺癌(這也是最普遍的癌症，還有前列腺癌和大腸直腸癌)是臨床試驗最多的兩種癌症，不過，在過去兩年，這兩種癌症的研究數量呈減少趨勢，其他癌症的研究則增加。
【糖尿病加強內分泌研究】
此篇回顧檢視2005年10月至2007年9月間，在美國臨床試驗登記有案的產業界贊助的第2至4期介入式研究，這段期間內大部份登記的試驗都是腫瘤科，其次為CNS 異常、心臟科、感染症、內分泌與呼吸道疾病。
2005年10月至2007年9月間登記有案的產業贊助第2至4期介入研究
| 第 1 年 |
| 第 2 年 |
| 總數 |
| 治療 / 疾病領域
| 協定 (n) | 處所 (n) | 協定 (n) | 處所 (n) | 協定 (n) | 處所 (n) | 腫瘤
| 405 | 13,375 | 419 | 10,520 | 824 | 23,895 | CNS 異常
| 337 | 10,141 | 333 | 5753 | 670 | 15,894 | 心臟科
| 346 | 11,166 | 257 | 6888 | 603 | 18,054 | 感染症
| 310 | 6049 | 256 | 4572 | 566 | 10,621 | 內分泌
| 272 | 11,120 | 276 | 5677 | 548 | 16,797 | 呼吸道
| 144 | 4637 | 160 | 4237 | 304 | 8874 |
在這兩年研究期間，腫瘤科、內分泌和風濕科在第二年登記的研究協定比第一年多；不過，心臟科的研究從第一年的346件減少到第二年的257件。
糖尿病是被研究最多的疾病，在這兩年期間有356件新登記的試驗，使得內分泌科成為最常被研究領域的第五名，
Nature. 印刷前於線上發布。2008年8月25日。 | |
Oncology Research Busy, With More Trials Than Other Therapeutic Areas
By Michael O'Riordan
Medscape Medical News
August 28, 2008 — The number of studies into oncology, endocrinology, and respiratory diseases is on the rise, while the number of registered cardiology studies declined during a recent 2-year period, according to the results of a new study. Cancer remains the most studied disease, according to the report, with cardiology third behind the number of studies for central nervous system (CNS) disorders.
"Breast cancer and lung cancer (which are also the most prevalent cancers, together with prostate cancer and colorectal cancer) are the 2 cancers with the greatest amount of clinical trial activity," writes Johan Karlberg, MD, from the University of Hong Kong, in a new review of clinical trials published online August 25 in Nature. "Although the 2 leading cancer indications show a decrease in the number of studies over the past 2 years, other cancer types showed strong growth."
Diabetes Boosts Endocrinology Research
The review examines trends in industry-sponsored phase 2 to 4 interventional studies registered with the American clinical-trials registry between October 2005 and September 2007. The most registered trials during this time period were in oncology, followed by studies of CNS disorders, cardiology, infectious disease, endocrinology, and respiratory diseases.
Industry-Sponsored Phase 2 to 4 Interventional Studies Registered Between October 2005 and September 2007 | Year 1 | | Year 2 | | Total | | | Therapeutic/disease area | Protocols (n) | Sites (n) | Protocols (n) | Sites (n) | Protocols (n) | Sites (n) | | Oncology | 405 | 13,375 | 419 | 10,520 | 824 | 23,895 | | CNS disorders | 337 | 10,141 | 333 | 5753 | 670 | 15,894 | | Cardiology | 346 | 11,166 | 257 | 6888 | 603 | 18,054 | | Infectious | 310 | 6049 | 256 | 4572 | 566 | 10,621 | | Endocrinology | 272 | 11,120 | 276 | 5677 | 548 | 16,797 | | Respiratory | 144 | 4637 | 160 | 4237 | 304 | 8874 |
Over the 2-year study period, oncology, endocrinology, and rheumatology had more registered study protocols in the second year than the first. Studies in cardiology, however, declined from 346 registered protocols in year 1 to 257 registered studies in the second year.
Diabetes is the most studied disease, with 356 new trials registered during the 2-year period, and contributed to making endocrinology the fifth largest therapeutic area studied.
Nature. Published online before print August 25, 2008.
|
|
|
